Sec Form 13G Filing - ADAR1 Capital Management LLC filing for Kala Pharmaceuticals, Inc. (KALA) - 2025-02-14

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes (i) 260,182 shares of common stock, par value $0.001 per share ("Common Stock") held by ADAR1 Partners, LP and (ii) 38,773 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of February 14, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC., ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.(2) Based on 6,091,182 shares of Common Stock of KALA BIO, Inc. (the "Issuer") outstanding as of December 31, 2024 reported in the Issuer's prospectus, filed with the SEC on February 4, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes 260,182 shares of Common Stock by ADAR1 Partners, LP as of February 14, 2025. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP.(2) Based on 6,091,182 shares of Common Stock of the Issuer outstanding as of December 31, 2024 reported in the Issuer's prospectus filed with the SEC on February 4, 2025.


SCHEDULE 13G



Comment for Type of Reporting Person:  (1) Includes (i) 260,182 shares of Common Stock held by ADAR1 Partners, LP and (ii) 38,773 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC as of February 14, 2025. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.(2) Based on 6,091,182 shares of Common Stock of the Issuer outstanding as of December 31, 2024 reported in the Issuer's prospectus filed with the SEC on February 4, 2025.


SCHEDULE 13G


 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/14/2025
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/14/2025
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:02/14/2025
primary_doc.xml